Chanticleer — Merger or Acquisition (November 2019)
19 slides from Chanticleer's merger presentation, Nov 12, 2019

Slide 1: Corporate Presentation
§ SONNET BioTherapeutics insforwardiooking statements that do notguarantee future perfomance Corporate Presentation November 2019

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements about Sonnet BioTherapeutics based on management's current expectations which are subject to known and unknown uncertainties and risks. Words such as “anticipated,” “initiate,” “expect,” “intend,” “plan,” “believe,” “se

Slide 3: Corporate Background
Corporate Background Incorporated in New Jersey » Headquarters: Princeton, New Jersey » Other Locations: New York City, Geneva *« Employees, Consultants and Contracted Scientists/Experts: Approximately 30 people * Internal Pipeline Focus: Oncology » Proprietary technology platform » Existing licensi

Slide 4: Corporate Highlights
Corporate Highlights Sonnet is a clinicalstage biopharmaceutical company with a proprietary, modular biologic drug development platform We have a deep knowledge of cytokine biology, complemented by extensive drug discovery and development expertise Our corporate strategy comprises an internal therap

Slide 5: The Sonnet Platform
The Sonnet Platform Asset generation capabilities across major biologic drug classes Five Filed Patent Applications: * FyAB design for numerous targets + Immunotherapy o Drug conjugation o Combination with checkpoint inhibitors + Vaccine + Bone Metastasis © CART

Slide 6: The Sonnet Technology Advantage
The Sonnet Technology Advantage Sonnet’s Fully Human Albumin Binding (F,AB) technology utilizes a single chain antibody fragment (scFv) capable of delivering one or two active drug compounds + Therapeutic payloads attached via flexible linker peptides Following administration, Sonnet's FyAB- derived

Slide 7: Pipeline Overview
Pipeline Overview First wave pipeline will target IL-6, IL-12, IL-15, IL-18, GMcSF and TGFp 8> FyAB Platform Program Indications Chemotherapy Induced SONEO8O lew: close: IL=6} Peripheral Neuropathy” SON-1010 (IL12-F,AB) Undisclosed Solid Tumor SON-1210 (IL15-F,AB-IL12) Undisclosed Solid Tumor SON-20

Slide 8: IL-6: A Disease Modifier of CIPN
IL-6: A Disease Modifier of CIPN In peripheral neurons, IL-6 triggers a series of pathways for the maintenance of mitochondrial function and axonal regeneration. CIPN Patient Population* + >50% of cancer patients receiving chemotherapy develop CIPN + CIPN peak prevalence as high as 70% + New cases u

Slide 9: IL-6 Intrinsically Reactivates Axonal Growth
IL-6 Intrinsically Reactivates Axonal Growth IL-6 maintains / restores nerve fiber density IL-6 restores sensation Intraepidermal nerve fibers density * Rats (n = 10/group) 0 rT * Rats (n = 10/group) Taxol (6mg/kg/week, ip.) ca ag * Cisplatin (2mg/kg, i-p.) cars ro a 3° = = RRRREMA? 00 ou oe on oo b

Slide 10: SON-080: Clinical History
SON-080: Clinical History Low dose recombinant human IL-6 is safe in cancer patients In Phase | studies comprising 214 total cancer patients: SC delivery of IL-6 doses dependently increases plasmatic IL-6, with plasmatic t1/2~ 4 hours Innone of the trials was exacerbation of tumour burden observed I

Slide 11: FHAB Constructs IL-12 and IL-15: Pharmacokinetic Half Life
FyAB Constructs IL-12 and IL-15: Pharmacokinetic Half Life The aim of this study was to demonstrate in mice, the pharmacokinetic (pK) behavior of naked IL-12 and IL-15 compared to the same interleukins linked to Sonnet’s F4AB domain Method: 8 mice C57B/ TP, Age 9.5 weeks dose IV, sacrificed @ 5, 15,

Slide 12: anti-TGFβ and anti-TGFβ-FHAB: Evaluating Tumor Accumulation
anti-TGFg and anti-TGFp-F,AB: Evaluating Tumor Accumulation An in vivo Demonstration of F,AB Proof-of-Concept Western blot analysis of Mouse 4T1 (TGFp-positive) tumor (~150mm®?) extracts from mice terminated at 0.5, 4, 12 and 24-hours post IV injection with 100 ug/mouse of F,AB, anti-TGFp (4D9M) and

Slide 13: IL12-FHAB vs IL-12: Tumor Volume Reduction
IL12-F,AB vs IL-12: Tumor Volume Reduction Comparison of Tumor Volumes Between Groups on Day 10 Post Treatment (Day 0 @ 100 mm?) 3000, 1L12 vs 1L12-FyAB . Single Dose E MM GI: Vehicle ee E 2 A MM G2: 112 S00: 2 “Mm G3: ILI2F,AB os 3 $ > 2 , MM Ga L12 108s Bis 2 MM G5: IL12-F,AB 3 = ME Gé: IL12 0 2 4

Slide 14: IL12-FHAB vs IL-12: Survival Data
8 IL12-F,AB vs IL-12: Survival Data x o id 604 404 % Animal Survived to 2000mm? Single Dose Median Days for 50% Tumor MM GI: Vehicle each 2o90mm"3 a 10 G2: IL12 @ 12 ‘ G3: anf Sa @ 14 a 12 G4: IL12 5 a 10, * G5: san “se ze ri = a a5 * Gé: IL12 +o, HO _Oae SS ‘* Equal molar IL-12 concentrations Compa

Slide 15: IL12-FHAB vs IL-12: Additional Tumor Reduction Data
IL12-F,AB vs IL-12: Additional Tumor Reduction Data Evaluation of Single Dose (SD) IL12-F,,AB (1.3ug) vs IL-12 (80ug) in B16F1O Melanoma (established @100 mm3, n=8) =@® Placebo a: 1L12-F, AB} (1.3ug, SD) = Molar I-12 (1pg) and 1L12-F4AB (1.3ug) are molar equivalent and have similar bioactivity, in A

Slide 16: IL15-FHAB-IL12 vs IL12-FHAB
IL15-FAB-IL12 vs IL12-F,AB Single I.V. Dose @ 100 mm® SC B16F10 Day 10 Tumor Volume (n=8) 1500 Sonnet Bi-Specific Construct 1L15-F,AB-IL12 Synergistic Biologic Activity: 1000 IL-12: 4 IL-15 alpha receptor, IFN, 500 NK/T cells, THI and | Treg IL-15: 7 IL-12beta I receptor, NK | cells & | CD8 memory l

Slide 17: IL15-FHAB-IL12 vs Concomitant IL-12 and IL-15
IL15-F,,AB-IL12 vs Concomitant IL-12 and IL-15 Day 11 hha. 1L15-F,,AB-IL12 shows better reduction than IL12-F,,AB-IL15 or free, concomitantly dosed IL-12 and IL-15 Day 11 vehicle at +3000m3 not shown HM IL-12 (5g) + IL-15 (ug) ME 1L12-FYAB-IL15 (1.5yg) MMB IL12-FAB-IL15 (6g) (@ 1L15-FYAB-L12 (1.5yg)

Slide 18: Execution Efficiency
Execution Efficiency Integrating a Best-in-Class Platform with a World-Class Development Strategy Cell Line - 1L12-F,AB Sartorius 1L15-FyAB-IL12 7 Exploring innovative cho Leadership: Analytics - clinical plans | seed SONNET Bio-oulsource + Latham BioPharm 1L12-FAB IL-6 1L15-F,AB-IL12 Identified CRO

Slide 19: Leadership
Leadership Accomplished management team with deep experience in biotechnology ©@3 ® Pankaj Mohan, PhD Founder, CEO & Chairman Biotechnology entrepreneur with start up, ceademic, large biopharma and government expevence. Founded Oncobiotogics in 2011 and led it to a successful IPOin 2016 (Nasdag: ONS
Source: SEC EDGAR · 425 filed Nov 12, 2019
More decks from Chanticleer Holdings Inc
Sonnet BioTherapeutics Holdings — Investor Presentation (September 2024)34 slides · Sep 9, 2024
Sonnet BioTherapeutics Holdings — Investor Presentation (June 2024)33 slides · Jun 14, 2024
Sonnet BioTherapeutics Holdings — Investor Presentation (May 2024)31 slides · May 14, 2024
Sonnet BioTherapeutics Holdings — Technical Presentation (April 2023)15 slides · Apr 18, 2023
Sonnet BioTherapeutics Holdings — Corporate Update (November 2022)12 slides · Nov 2, 2022
Cowen Healthcare Conference 202022 slides · Mar 3, 2020